B17. EMERGING DATA ON DISEASE AND SYMPTOM BASED THERAPEUTICS FOR PATIENTS WITH IPF

查看最新文献

147

B17. EMERGING DATA ON DISEASE AND SYMPTOM BASED THERAPEUTICS FOR PATIENTS WITH IPF - 最新文献

The Effect of Oral Nalbuphine Extended Release on Patient-reported Outcome Measures in Patients With Idiopathic-Pulmonary-Fibrosis-related Chronic Cough

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2782 T. M. Maher, C. Avram, E. Bortey, S. Hart, N. Hirani, P. Molyneaux, J. Porter, T. Sciascia

Long-term Safety Data of Inhaled Pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease (ILD) Patients

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2778 F. Woodhead, D. Nair, H. Bao, L. Freeman, K. Otto, M. Surber

Generalizability of Pharmaceutical Randomized Controlled Trials for Idiopathic Pulmonary Fibrosis

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2784 Y. Khor, M. Schulte, K. Johannson, V. Marcoux, J. Fisher, D. Assayag, H. Manganas, N. Khalil, M. Kolb, C. Ryerson, for the Austin ILD Registry and CARE-PF Investigat

查看全部

免责声明：
本页显示期刊或杂志信息，仅供参考学习，不是任何期刊杂志官网，不涉及出版事务，特此申明。如需出版一切事务需要用户自己向出版商联系核实。若本页展示内容有任何问题，请联系我们，邮箱：info@booksci.cn，我们会认真核实处理。